Status:
COMPLETED
DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines
Lead Sponsor:
AstraZeneca
Conditions:
Diabetes Mellitus Type 2
Crestor, Rosuvastatin
Eligibility:
All Genders
18-70 years
Brief Summary
The purpose of this study is to determine in DM II patients the efficacy of Crestor in obtaining the new European LDL cholesterol guidelines.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Diabetes Mellitus Type 2, LDL-C \> 2,5 mmol/l, no cholesterol lowering medication used last 3 months, starts with Crestor 10 mg, permission to use patient data by AZ
Exclusion
Key Trial Info
Start Date :
May 1 2004
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
2500 Patients enrolled
Trial Details
Trial ID
NCT00233649
Start Date
May 1 2004
Last Update
November 19 2010
Active Locations (222)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
's Gravenmoer, Netherlands
2
Research Site
's-Hertogenbosch, Netherlands
3
Research Site
Aalten, Netherlands
4
Research Site
Alkmaar, Netherlands